Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) Return on Sales (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Return on Sales for 5 consecutive years, with 0.51% as the latest value for Q1 2026.

  • For Q1 2026, Return on Sales rose 280.0% year-over-year to 0.51%; the TTM value through Mar 2026 reached 0.76%, up 346.0%, while the annual FY2025 figure was 1.26%, 479.0% up from the prior year.
  • Return on Sales hit 0.51% in Q1 2026 for Phathom Pharmaceuticals, down from 0.37% in the prior quarter.
  • Across five years, Return on Sales topped out at 18.41% in Q3 2023 and bottomed at 116.65% in Q4 2023.
  • Average Return on Sales over 5 years is 6.81%, with a median of 0.51% recorded in 2026.
  • Year-over-year, Return on Sales plummeted -12237bps in 2023 and then surged 11414bps in 2024.
  • Phathom Pharmaceuticals' Return on Sales stood at 5.72% in 2022, then tumbled by -2138bps to 116.65% in 2023, then soared by 98bps to 2.51% in 2024, then surged by 85bps to 0.37% in 2025, then tumbled by -38bps to 0.51% in 2026.
  • According to Business Quant data, Return on Sales over the past three periods came in at 0.51%, 0.37%, and 0.61% for Q1 2026, Q4 2025, and Q3 2025 respectively.